CD95 (also known as FAS or APO-1) came to the fore in 1989 as a potential therapeutic target in cancer owing to its function as a trigger of apoptosis.16, 17 Activation of CD95 leads to recruitment and activation of caspases that irreversibly induce apoptosis.18 In addition, phosphorylation of tyrosine within CD95 intracellular death domain has been observed following binding by CD95 ligand (CD95L).19, 20. Here, FAS is linked to cancer.